Review
BibTex RIS Cite

Management of the Gastrointestinal System Bleeding Caused by Direct-Acting Oral Anticoagulants

Year 2021, Volume: 38 Issue: 2s, 33 - 37, 18.03.2021

Şencan Acar Ahmet Eminler

Abstract

Direct-acting oral anticoagulants include dabigatran, which is a thrombin inhibitor, and rivaroxaban, apixaban, and edoxaban, which are anti-Xa agents. These are administered in the secondary prophylaxis and treatment of venous thromboembolism (VTE) and pulmonary embolism (PE), in the prophylaxis of VTE that may develop after major elective orthopedic surgery, in reducing stroke and systemic embolism that may occur in non-valvular atrial fibrillation, whereas its use in acute coronary syndrome is still controversial. Although it is specified that direct-acting oral anticoagulants are as effective as heparin therapy and reduce the risk of bleeding due to all causes, many important studies have also reported that they increase the risk of gastrointestinal system (GIS) bleeding.

Keywords

Gastrointestinal Bleeding Direct Acting Oral Anticoagulants Endoscopy

Project Number

Yok

References

  • Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, et al., 2015. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 350:h1857.

Year 2021, Volume: 38 Issue: 2s, 33 - 37, 18.03.2021

Şencan Acar Ahmet Eminler

Abstract

Supporting Institution

Yok

Project Number

Yok

Thanks

Doç Dr Talat Ayyıldız'a nazik daveti için teşekkür ederiz

References

  • Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, et al., 2015. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 350:h1857.
There are 1 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Clinical Research
Authors

Şencan Acar 0000-0001-8086-0956

Ahmet Eminler 0000-0003-1402-5682

Project Number Yok
Publication Date March 18, 2021
Submission Date September 10, 2020
Acceptance Date November 18, 2020
Published in Issue Year 2021 Volume: 38 Issue: 2s

Cite

APA Acar, Ş., & Eminler, A. (2021). Management of the Gastrointestinal System Bleeding Caused by Direct-Acting Oral Anticoagulants. Journal of Experimental and Clinical Medicine, 38(2s), 33-37.
AMA Acar Ş, Eminler A. Management of the Gastrointestinal System Bleeding Caused by Direct-Acting Oral Anticoagulants. J. Exp. Clin. Med. March 2021;38(2s):33-37.
Chicago Acar, Şencan, and Ahmet Eminler. “Management of the Gastrointestinal System Bleeding Caused by Direct-Acting Oral Anticoagulants”. Journal of Experimental and Clinical Medicine 38, no. 2s (March 2021): 33-37.
EndNote Acar Ş, Eminler A (March 1, 2021) Management of the Gastrointestinal System Bleeding Caused by Direct-Acting Oral Anticoagulants. Journal of Experimental and Clinical Medicine 38 2s 33–37.
IEEE Ş. Acar and A. Eminler, “Management of the Gastrointestinal System Bleeding Caused by Direct-Acting Oral Anticoagulants”, J. Exp. Clin. Med., vol. 38, no. 2s, pp. 33–37, 2021.
ISNAD Acar, Şencan - Eminler, Ahmet. “Management of the Gastrointestinal System Bleeding Caused by Direct-Acting Oral Anticoagulants”. Journal of Experimental and Clinical Medicine 38/2s (March 2021), 33-37.
JAMA Acar Ş, Eminler A. Management of the Gastrointestinal System Bleeding Caused by Direct-Acting Oral Anticoagulants. J. Exp. Clin. Med. 2021;38:33–37.
MLA Acar, Şencan and Ahmet Eminler. “Management of the Gastrointestinal System Bleeding Caused by Direct-Acting Oral Anticoagulants”. Journal of Experimental and Clinical Medicine, vol. 38, no. 2s, 2021, pp. 33-37.
Vancouver Acar Ş, Eminler A. Management of the Gastrointestinal System Bleeding Caused by Direct-Acting Oral Anticoagulants. J. Exp. Clin. Med. 2021;38(2s):33-7.
 Download Cover Image

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.